Single-Dose Breakthrough: Acoziborole Signals End for Sleeping Sickness

The introduction of acoziborole, the first single-dose oral treatment for Human African Trypanosomiasis (HAT), marks a historic milestone in global health and the fight against neglected tropical diseases. For over a century, sleeping sickness—transmitted by the tsetse fly—was a death sentence or required harrowing, often lethal, treatments. Early interventions, such as melarsoprol, were arsenic-derived and so toxic they killed roughly 5% of patients who received them. While subsequent treatments like NECT (nifurtimox-eflornithine combination therapy) and fexinidazole improved safety, they still required complex administration or multi-day pill regimens that were difficult to maintain in remote, conflict-affected regions. Acoziborole fundamentally changes this paradigm by offering a highly effective cure in a single oral dose, potentially removing the final logistical barriers to total disease elimination by 2030.

The clinical significance of acoziborole is rooted in its simplicity and efficacy. In pivotal Phase 2/3 trials conducted primarily in the Democratic Republic of Congo (DRC) and Guinea, the drug demonstrated a 95% success rate in patients with both early and late-stage disease. This is a critical breakthrough because previous treatments required a painful lumbar puncture (spinal tap) to determine if the parasite had crossed the blood-brain barrier before a treatment could be selected. Acoziborole’s ability to treat both stages means healthcare workers can now adopt a screen-and-treat approach. Once a patient tests positive via a simple rapid diagnostic test, they can be given the single dose immediately, eliminating the need for hospitalization, specialized nursing care, or invasive diagnostic procedures.

“

Furthermore, while acoziborole targets Trypanosoma brucei gambiense (responsible for 92% of cases), continued R&D is necessary for the more acute rhodesiense form of the disease found in Eastern Africa.

From a pharmaceutical and industry perspective, acoziborole is a premier example of the success of the Product Development Partnership (PDP) model. Developed by the Drugs for Neglected Diseases initiative (DNDi) in close collaboration with Sanofi, the project demonstrates how a major pharmaceutical company can leverage its manufacturing and regulatory expertise to address diseases that offer no traditional commercial profit. Sanofi has committed to providing the drug at no cost to the World Health Organization (WHO) for distribution in endemic countries. This philanthropic alignment ensures that the breakthrough reaches the most vulnerable populations without the price barriers typically associated with novel therapeutics. For Sanofi, the project serves as a cornerstone of its Environmental, Social, and Governance (ESG) strategy, proving that high-science innovation can be applied to global health equity.